BR-790

Main purpose: Phase I (dose escalation phase): To evaluate the safety and tolerability of BR790 tablets combined with anlotinib hydrochloride capsules in the treatment of patients with advanced non-small cell lung cancer, and to determine the maximum tolerated dose of the combination therapy and the recommended dose of the combination therapy in Phase II clinical trials; Phase II (dose expansion phase): To evaluate the effectiveness of BR790 tablets combined with anlotinib hydrochloride capsules in the treatment of advanced non-small cell lung cancer (assessed according to the solid tumor evaluation standard RECIST V1.1). Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of BR790 and anlotinib when administered in combination, and to preliminarily evaluate the effect of anlotinib on BR790 PK when the two drugs are used in combination. Exploratory purpose: 1. Retrospectively analyze the relationship between tumor KRAS, BRAF, NF1 and other genetic abnormalities and efficacy; 2. Explore the relationship between dose-exposure-response.